Postpartalni bipolarni afektivni poremećaj tip 2: Prikaz slučaja
Sažetak
Uvod: Period nakon porođaja se smatra periodom povećanog rizika od nastanka bipolarnog afektivnog poremećaja tipa II (BDII). Postpartalni BDII je prema nama dostupnim podacima, izuzetno zanemarena oblast posmatranja, sa negativnim posledicama po majku, potomstvo i porodicu kao celinu.
Prikaz slučaja: Opisujemo slučaj pacijentkinje sa simptomima depresivne epizode atipičnih karakteristika nakon porođaja, sa jednom blagom suspektno postpartalno depresivnom i više prethodno detektovanih epizoda sličnih hipomaniji i porodičnom istorijom suspektne postpartalne depresije i bipolarnog afektivnog poremećaja. Prepisali smo escitalopram 20mg u kombinaciji sa lamotriginom od 200mg. Pacijentkinja je trenutno na propisanoj terapijskoj dozi, bez detektovanih ozbiljnih neželjenih ili nepredviđenih događaja, i od tada nije bilo recidiva.
Zaključak: Žene tokom trudnoće i postpartalno treba da budu podvrgnute skriningu na BDII. Na osnovu iskustva prikazanog slučaja, kombinacija escitaloprama i lamotrigina je pokazala dobre rezultate, a usklađena je sa svim preporučenim smernicama za lečenje BDII.
Reference
References
1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing Text Citation: (American Psychiatric Association, 2013).
2. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007; 64:543–552.
3. Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press. 2016.
4. WHO. International Statistical Classification of Diseases and Related Health Problems, 11th Revision: ICD-11. World Health Organization, Geneva, June 2018. https://doi.org/10.1071/SH17086
5. Stojanov J, Stankovic M, Zikic O, Stankovic M, Stojanov A. The risk for nonpsychotic postpartum mood and anxiety disorders during the COVID-19 pandemic. Int J Psychiatry Med. 2021;56(4):228-239.
6. Hirschfeld RM, Williams JB, Spitzer RL et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157(11):1873–5.
7. Hidalgo-Mazzei D, Mateu A, Undurraga J et al. e-HCL-32: a useful, valid and user friendly tool in the screening of bipolar II disorder. Compr Psychiatry. 2015;56:283-8.
8. Glover V, Liddle P, Taylor A et al. Mild hypomania (the highs) can be a feature of the first postpartum week: association with later depression. Br J Psychiatry 1994;164, 517–521.
9. Balázs J, Benazzi F, Rihmer Z et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91, 133–138.
10. Propper L, Sandstrom A, Rempel S et al. Attention-deficit/hyperactivity disorder and other neurodevelopmental disorders in offspring of parents with depression and bipolar disorder. Psychol Med. 2021;18:1-8.
11. Yatham L, Kennedy S, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11, 225–255.
12. Viguera AC, Whitfield T, Baldessarini RJ et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007;164(12):1817–24.